Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.610
+0.290 (12.50%)
At close: Aug 13, 2025, 4:00 PM
2.660
+0.050 (1.92%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$65,250
Profits / Employee
-$922,264
Market Cap
893.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVB News
- 7 days ago - Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 9 days ago - Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - Business Wire
- 20 days ago - Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - Business Wire
- 7 weeks ago - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers - Business Wire
- 2 months ago - Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - GlobeNewsWire
- 2 months ago - US FDA approves Nuvation Bio's lung cancer therapy - Reuters
- 2 months ago - U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Business Wire
- 3 months ago - Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting - Business Wire